Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP-7888 in Myelodysplastic Syndrome (MDS)
NCT02436252Phase 2Completed
- Sponsor
- Sumitomo Pharma
- Start
- May 2015
- Primary completion
- Mar 2020
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of adegramotide in myelodysplastic syndrome (MDS), sponsored by Sumitomo Pharma. Started May 2015; status: completed.
02
Drugs
adegramotide
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02436252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02436252.